KIR3DL2 and neoplasm: It is possible that targeting KIR3DL2 with anti-KIR3DL2 mAbs (aKIR3DL2 mAbs) may not only directly affect tumor T cells but circumvent an important cancer immune-suppressive mechanism by restoring NK cell functions.